Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19542925 | 0.94 | TSHR (0.33) | TSHRTDP1MAPK1ALDH1A1 | |
| SCHEMBL12555908 | 0.94 | TSHR (0.33) | TSHRTDP1MAPK1ALDH1A1 | |
| SCHEMBL19543074 | 0.86 | THRB (0.34) | — | |
| SCHEMBL19543415 | 0.84 | TSHR (0.33) | TSHRTDP1ALDH1A1 | |
| SCHEMBL14890729 | 0.84 | ALDH1A1 (0.32) | TSHRTDP1ALDH1A1 | |
| SCHEMBL9249356 | 0.84 | MAPK1 (0.32) | MAPK1 | |
| SCHEMBL754497 | 0.83 | MAPK1 (0.36) | TSHRTDP1MAPK1ALDH1A1 | |
| SCHEMBL26380282 | 0.82 | — | — | |
| SCHEMBL13538691 | 0.82 | — | — | |
| SCHEMBL13537006 | 0.82 | TSHR (0.32) | TSHRTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8951998-B2 | Quinoxaline-containing compounds as hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8951998-B2 | Quinoxaline-containing compounds as hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2015-02-10 | — | — | US | disclosed |
| US-8324155-B2 | Quinoxaline-containing compounds as hepatitis C virus inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2012-12-04 | — | — | US | disclosed |
| US-20100003214-A1 | QUINOXALINE-CONTAINING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2010-01-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100003214-A1 | QUINOXALINE-CONTAINING COMPOUNDS AS HEPATITIS C VIRUS INHIBITORS | CYP3A4, CYP3A5, KEAP1 | TSHR 4866/4885TDP1 3004/4885MAPK1 1952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.